On Wednesday, Johnson & Johnson JNJ reported a fourth-quarter adjusted EPS of $2.04, down 10.9% yr over yr, beating the consensus of $2.01.
The pharmaceutical large reported gross sales of $22.52 billion, up 5.3% yr over yr and beating the consensus of $22.44 billion.
Operational development was 6.7%, and adjusted operational development was 5.7%.
Progressive Drugs gross sales elevated to $14.33 billion, up 4.4% (+6.1% adjusted operational).
Development was pushed by Darzalex (daratumumab), Erleada (apalutamide), Carvykti (ciltacabtagene autoleucel), Tremfya (guselkumab), and Spravato (esketamine), pushed by continued robust share beneficial properties and market development. Total most cancers gross sales elevated to $5.49 billion.
Additionally Learn: FDA Approves Johnson & Johnson’s Therapy As First Monotherapy For Therapy-Resistant Despair
Development was partially offset by Stelara (ustekinumab). Stelara gross sales fell 14.7% to $2.35 billion. Darzalex gross sales rose 20.9% to $3.08 billion. The corporate’s most cancers cell remedy, Carvykti, generated gross sales of $334 million.
MedTech gross sales elevated 6.7% to eight.19 billion, driven by world process development, new product efficiency, and the Shockwave deal. Development was partially offset by endocutter merchandise in Superior Surgical procedure.
Steerage: Johnson & Johnson expects 2025 gross sales of $90.9 billion—$91.7 billion, in comparison with the consensus of $90.99 billion. The Medtech large expects 2025 adjusted EPS of $10.75–$10.95 versus a consensus of $10.59.
The corporate expects to speed up the launch of newly launched merchandise within the MedTech section, with the complete advantage of the Shockwave acquisition via Might. JNJ sees normalized process quantity and seasonality.
Earlier this month, Johnson & Johnson agreed to amass Intra-Mobile Therapies Inc. ITCI for $132.00 per share in money for a complete fairness worth of roughly $14.6 billion.
Intra-Mobile Therapies is a biopharmaceutical firm centered on growing and commercializing therapeutics for central nervous system (CNS) problems.
Value Motion: Finally examine on Wednesday, JNJ inventory was down 1.69% to $145.65 throughout the premarket session.
Learn Subsequent:
Picture By Sundry Pictures By way of Shutterstock
Overview Ranking:
Speculative
Market Information and Knowledge dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
